Page last updated: 2024-12-10
ostruthin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5281420 |
| CHEMBL ID | 1812645 |
| CHEBI ID | 69833 |
| SCHEMBL ID | 2936116 |
| SCHEMBL ID | 2936121 |
| MeSH ID | M0052811 |
Synonyms (37)
| Synonym |
|---|
| coumarin, 6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-,(e)- |
| ostruthine |
| nsc83434 |
| 2h-1-benzopyran-2-one,6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-,(e)- |
| 6-[(2e)-3,7-dimethylocta-2,6-dienyl]-7-hydroxy-chromen-2-one |
| ACON1_001218 |
| coumarin,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)- |
| 2h-1-benzopyran-2-one,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)- |
| nsc-83434 |
| 6-geranyl-7-hydroxycoumarin |
| MEGXP0_001198 |
| C09281 |
| 148-83-4 |
| ostruthin |
| 6-[(2e)-3,7-dimethylocta-2,6-dienyl]-7-hydroxychromen-2-one |
| CHEMBL1812645 |
| chebi:69833 , |
| xhk3rr9bor , |
| nsc 83434 |
| ccris 8087 |
| 2h-1-benzopyran-2-one, 6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)- |
| unii-xhk3rr9bor |
| coumarin, 6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)- |
| 6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxycoumarin |
| (e)-6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-2h-1-benzopyran-2-one |
| (e)-6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxycoumarin |
| 6-(3,7-dimethyl-2,6-octadienyl)umbelliferone |
| ostruthin [mi] |
| (e)-6-(3,7-dimethylocta-2,6-dien-1-yl)-7-hydroxy-2h-chromen-2-one |
| SCHEMBL2936116 |
| SCHEMBL2936121 |
| 2h-1-benzopyran-2-one,6-[(2e)-3,7-dimethyl-2,6-octadien-1-yl]-7-hydroxy- |
| 6-geranyl-7-hydroxycoumarin, >=95% (lc/ms-elsd) |
| 2h-1-benzopyran-2-one, 6-(3,7-dimethyl-2,6-octadienyl)-7-hydroxy-, (e)- (9ci) |
| Q21547160 |
| DTXSID601318569 |
| AKOS040735765 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Roles (1)
| Role | Description |
|---|---|
| metabolite | Any intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Drug Classes (1)
| Class | Description |
|---|---|
| terpene lactone | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] | |
Bioassays (4)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID611882 | Antiproliferative activity in primary rat aortic VSMC assessed as inhibition of serum-induced DNA synthesis pretreated 30 mins prior serum addition measured after 48 hrs by BrdU incorporation assay | 2011 | Journal of natural products, Jun-24, Volume: 74, Issue:6 | Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation. |
| AID611885 | Cytotoxicity against primary rat aortic VSMC as cell viability at 30 uM by trypan blue exclusion assay (Rvb = 98+/-2%) | 2011 | Journal of natural products, Jun-24, Volume: 74, Issue:6 | Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation. |
| AID611886 | Antiproliferative activity against serum-stimulated primary rat aortic VSMC after 30 mins by resazurin conversion assay | 2011 | Journal of natural products, Jun-24, Volume: 74, Issue:6 | Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation. |
| AID611884 | Antiproliferative activity against serum-stimulated primary rat aortic VSMC at 30 uM after 30 mins by resazurin conversion assay | 2011 | Journal of natural products, Jun-24, Volume: 74, Issue:6 | Identification of ostruthin from Peucedanum ostruthium rhizomes as an inhibitor of vascular smooth muscle cell proliferation. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (8)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 2 (25.00) | 18.7374 |
| 1990's | 2 (25.00) | 18.2507 |
| 2000's | 1 (12.50) | 29.6817 |
| 2010's | 3 (37.50) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 26.00
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (26.00) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 8 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||